• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
TMB-related immune gene PAEP influences clear cell renal cell carcinoma progression and prognosis.
Eur J Med Res. 2026 Jan 17;31(1):280. doi: 10.1186/s40001-025-03672-3.
2
Deciphering potential molecular mechanisms in clear cell renal cell carcinoma based on the ubiquitin-conjugating enzyme E2 related genes: Identifying UBE2C correlates to infiltration of regulatory T cells.基于泛素结合酶E2相关基因解析透明细胞肾细胞癌的潜在分子机制:鉴定与调节性T细胞浸润相关的UBE2C
Biofactors. 2025 Jan-Feb;51(1):e2143. doi: 10.1002/biof.2143. Epub 2024 Nov 29.
3
A novel migrasome-associated lncRNA model for clear cell renal cell carcinoma prognosis and immune response prediction.
Sci Rep. 2025 Dec 11;16(1):1895. doi: 10.1038/s41598-025-31455-7.
4
Kinesin-related genes stratified the prognosis and immune responses of clear cell renal cell carcinoma.驱动蛋白相关基因可对透明细胞肾细胞癌的预后和免疫反应进行分层。
Eur J Med Res. 2025 Jul 14;30(1):621. doi: 10.1186/s40001-025-02880-1.
5
Integrative multi-omics analysis identifies a PTM-related immune signature and IRF9 as a driver in ccRCC.
Front Immunol. 2025 Dec 1;16:1707375. doi: 10.3389/fimmu.2025.1707375. eCollection 2025.
6
Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction.肾透明细胞癌中预后生物标志物的鉴定与验证:免疫-基质评分与生存预测
BMC Cancer. 2025 Jan 27;25(1):148. doi: 10.1186/s12885-025-13534-0.
7
Integrated Genomic and Functional Characterization of Palmitoylation in Clear Cell Renal Cell Carcinoma.
Hum Mutat. 2025 Nov 29;2025:4647115. doi: 10.1155/humu/4647115. eCollection 2025.
8
Comprehensive analysis of heat shock protein 110, 90, 70, 60 families and tumor immune microenvironment characterization in clear cell renal cell carcinoma.透明细胞肾细胞癌中热休克蛋白110、90、70、60家族的综合分析及肿瘤免疫微环境特征
Sci Rep. 2025 Jan 2;15(1):469. doi: 10.1038/s41598-024-84834-x.
9
A SWI/SNF complex-related genes signature predicts prognosis and immune infiltration in ccRCC with KCNK5 as a novel biomarker.
Sci Rep. 2025 Nov 21;15(1):41423. doi: 10.1038/s41598-025-25283-y.
10
Integrative bulk and single-cell transcriptomic analysis identifies a migrasome-associated lncRNA signature predictive of prognosis and immune landscape in clear cell renal cell carcinoma.整合性批量和单细胞转录组分析确定了一种与迁移体相关的长链非编码RNA特征,可预测透明细胞肾细胞癌的预后和免疫格局。
Front Immunol. 2025 Aug 20;16:1638792. doi: 10.3389/fimmu.2025.1638792. eCollection 2025.

本文引用的文献

1
Single-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche in -mutant colorectal cancer.单细胞和空间转录组分析确定了突变型结直肠癌中的免疫抑制性空间生态位。
J Immunother Cancer. 2025 Dec 31;13(12):e013763. doi: 10.1136/jitc-2025-013763.
2
Mitochondrial Pathway Signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma.线粒体通路特征(MitoPS)可预测免疫治疗反应,并揭示NDUFB10是肺腺癌中的关键免疫调节因子。
J Immunother Cancer. 2025 Jul 31;13(7):e012069. doi: 10.1136/jitc-2025-012069.
3
Expression and Prognostic Significance of Ferroptosis-related Proteins SLC7A11 and GPX4 in Renal Cell Carcinoma.铁死亡相关蛋白 SLC7A11 和 GPX4 在肾细胞癌中的表达及预后意义。
Protein Pept Lett. 2023;30(10):868-876. doi: 10.2174/0109298665255704230920063254.
4
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.考比替尼联合阿特珠单抗治疗实体瘤患者的安全性和有效性:一项开放标签、多中心、多队列的 II 期研究。
ESMO Open. 2023 Apr;8(2):100877. doi: 10.1016/j.esmoop.2023.100877. Epub 2023 Mar 21.
5
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.组织病理学和蛋白质基因组学异质性揭示了透明细胞肾细胞癌侵袭性的特征。
Cancer Cell. 2023 Jan 9;41(1):139-163.e17. doi: 10.1016/j.ccell.2022.12.001. Epub 2022 Dec 22.
6
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research.针对癌症治疗的细胞死亡途径:细胞坏死、细胞焦亡、铁死亡和铜死亡研究的新进展。
J Hematol Oncol. 2022 Dec 8;15(1):174. doi: 10.1186/s13045-022-01392-3.
7
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View.欧洲泌尿外科协会肾细胞癌指南小组关于《2022年世界卫生组织肾脏肿瘤分类》的更新:泌尿外科医生的观点。
Eur Urol. 2023 Feb;83(2):97-100. doi: 10.1016/j.eururo.2022.11.001. Epub 2022 Nov 23.
8
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.三级淋巴结构在肾细胞癌中生成并扩增产生抗肿瘤抗体的浆细胞。
Immunity. 2022 Mar 8;55(3):527-541.e5. doi: 10.1016/j.immuni.2022.02.001. Epub 2022 Feb 28.
9
Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients.中国肾透明细胞癌患者的综合基因组图谱
Front Oncol. 2021 Sep 9;11:697219. doi: 10.3389/fonc.2021.697219. eCollection 2021.
10
Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.具有高肿瘤突变负担的甲状腺乳头状癌预后不良。
Int Immunopharmacol. 2020 Dec;89(Pt B):107090. doi: 10.1016/j.intimp.2020.107090. Epub 2020 Oct 19.

TMB-related immune gene PAEP influences clear cell renal cell carcinoma progression and prognosis.

作者信息

Yang Jie, Wu Guoliang, Wu Qian, Hu Xinming, Peng Zechun, Zhang Dan, He Shuming

机构信息

Department of Urology, The Second Affiliated Hospital of Hainan Medical University, No. 368 Yehai Road, Haikou, 570100, China.

Department of Clinical Pharmacy' People's Hospital of Daye City' The Second Affiliated Hospital of Hubei Polytechnic University' No. 26' Donggang Road, Daye, China.

出版信息

Eur J Med Res. 2026 Jan 17;31(1):280. doi: 10.1186/s40001-025-03672-3.

DOI:10.1186/s40001-025-03672-3
PMID:41547926
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12896064/
Abstract

BACKGROUND

Clear cell renal cell carcinoma (ccRCC) is a prevalent and aggressive form of kidney cancer with a poor prognosis. The tumor mutational burden (TMB) has been a subject of considerable interest in various cancer studies. However, the relationship between TMB and ccRCC has been inadequately explored. This study aimed to elucidate the role of TMB-related immune genes in ccRCC and the underlying molecular mechanisms.

METHODS

Somatic mutation data from 336 ccRCC patients were downloaded from The Cancer Genome Atlas (TCGA). The mutational spectrum was analyzed using the maftools software package. Based on the TCGA ccRCC cohort, we summarized the gene mutation profile. The TMB was calculated, and samples were categorized into high- and low-TMB groups. We then investigated the relationship between TMB and clinical characteristics. Additionally, we identified TMB-related immune genes by intersecting TMB-related differentially expressed genes with immune-related genes. Finally, we selected the immune genes most strongly associated with TMB and examined their expression levels in ccRCC cancer tissues. We further explored their roles and potential molecular mechanisms both in vivo and in vitro.

RESULTS

The most common mutations in the variant classification, variant type, and single nucleotide variant classes in ccRCC were analyzed bioinformatically. We found that a higher TMB was associated with poorer overall survival outcomes, younger age, and lower grade. Furthermore, we identified a novel TMB-related immune gene in ccRCC: the progestagen-associated endometrial protein (PAEP) gene. This gene was significantly overexpressed in ccRCC tissues and strongly associated with patient prognosis. Additionally, we observed that knockdown of PAEP significantly inhibited proliferation, migration, and invasion while promoting apoptosis in the 786-O and ACHN ccRCC cell lines. In vivo, the growth rate of subcutaneous xenografts in nude mice was significantly slowed after PAEP knockout. Mechanistically, the anti-cancer effects of PAEP knockout may be related to inhibition of the PI3K/Akt/NF-κB signaling pathway.

CONCLUSION

Our study suggests that PAEP may be a potential therapeutic target for ccRCC, providing a new theoretical basis for ccRCC clinical immunotherapy.

摘要